Pharsight Forms Drug Development Alliances With AstraZeneca, Quintiles | GenomeWeb

MOUNTAIN VIEW, Calif.--Pharsight, a clinical drug development software provider and consultancy here, has formed two partnerships: one with AstraZeneca R&D Molndal, of Sweden, and a broader one with Quintiles Transnational, a Research Triangle Park, NC-based provider of product development and commercialization services to the pharmaceutical industry.

The goal of the AstraZeneca alliance is to jointly deploy Pharsight's trial design software and methodologies for drug development to AstraZeneca's clinical development processes in a specific therapeutic area.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.